Computational and systems biologist Aviv Regev focuses on developing and applying experimental methods and machine learning algorithms to decipher intra- and intercellular circuits in cells in tissues. She is a pioneer of single cell and spatial genomics and has leveraged advances in technology to generate new insights in fields including immunology, neurobiology and cancer.
Regev is currently the Head of Genentech Research and Early Development (gRED), where she is responsible for all aspects of gRED's drug discovery and development. She is also a member of the expanded Corporate Executive Committee for Roche. Prior to Genentech, Regev served as Professor of Biology at MIT, and Chair of the Faculty, Core Member, and Founding Director of the Klarman Cell Observatory at the Broad Institute of MIT and Harvard, as well as an Investigator at the Howard Hughes Medical Institute.
Regev is a founding co-chair of the Human Cell Atlas. She is an elected member of the US National Academies of Science and Medicine, the American Academy of Arts and Sciences, and a recipient of multiple honors, including the L'Oreal-UNESCO For Women in Science International Award (2023), the Ernst Schering Prize (2021), the Vanderbilt Prize (2021), the 25th Keio Medical Science Prize (2020) and the Lurie Prize (2020).
Professional position
- Executive Vice President and Global Head, Genentech Research and Early Development, Genentech/Roche
Subject groups
-
Computer Sciences
Artificial intelligence, machine learning, vision
-
Molecules of Life
Cell biology (incl molecular cell biology)
-
Cell Biology
Cellular and humoral immunology, Genetics (excluding population genetics)
-
Patterns in Populations
Biological modelling
-
Health and Human Sciences
Molecular medicine
